A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT07306832
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
Pivekimab Sunirine
Sponsor
AbbVie